Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1434-1452

  Studerus, Erich ^a   Kometer, Michael ^a   Hasler, Felix ^a   Vollenweider, Franz X ^a  

^a University Hospital of Psychiatry Zurich   (Switzerland)

Author keywords

5 HT2A agonists; adverse effects; altered states of consciousness; dose response relationship; drug abuse; flashbacks; hallucinogens; human research; long term effects; psilocybin

Indexed keywords

PLACEBO; PSILOCYBINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG TOLERABILITY; EXPERIMENTAL STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LONG TERM CARE; MALE; MOOD CHANGE; NORMAL HUMAN; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOPHARMACOLOGY; PSYCHOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SAFETY; THINKING;

ADULT; AFFECT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; PERCEPTION; PSILOCYBINE; QUESTIONNAIRES; YOUNG ADULT;

EID: 83455162367     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110382466     Document Type: Article

References (111)

1. Abraham HD. A chronic impairment of colour vision in users of LSD. Br J Psychiatry. 1982 ; 140: 518-520 (Pubitemid 12100315)
2. Abraham HD. Visual phenomenology of the LSD flashback. Arch Gen Psychiatry. 1983 ; 40: 884-889 (Pubitemid 13025222)
3. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction. 1993 ; 88: 1327-1334 (Pubitemid 23302208)
4. Abraham HD, Duffy FH. Stable quantitative EEG difference in post-LSD visual disorder by spit-half analysis: evidence for disinhibition. Psychiatry Res. 1996 ; 67: 173-187 (Pubitemid 26344749)
5. Abraham HD, Duffy FH. EEG coherence in post-LSD visual hallucinations. Psychiatry Res. 2001 ; 107: 151-163 (Pubitemid 32868800)
6. Abraham HD, Wolf E. Visual function in past users of LSD: psychophysical findings. J Abnorm Psychol. 1988 ; 1988: 443-447 (Pubitemid 18266367)
7. Ametamey S, Vollenweider FX, Patt J, Bourquin D, Hasler F, Beer HF, et al. 11C-Radiolabeling of hallucinogenic psilocin, a potential radioligand for studying the role of serotonin receptors in psychotic symptom formation. J Labelled Comp Radiopharm. 1998 ; 41: 585-594 (Pubitemid 28308254)
8. Bodmer I Erinnerung an einen aussergewöhnlichen Bewusstseinszustand: Eine experimentelle Untersuchung zum autobiographischen Gedächtnis [Recollection of an altered state of consciousness: An experimental study on the autobiographic memory]. Berlin: VWB-Verlag für Wissenschaft und Bildung ; 1999 :
9. Braun I (1997) Zur quantitativen Beschreibung aussergewöhnlicher Bewusstseinszustände im fünfdimensionalen Raum: Eine empirische Studie [On the quantitative description of altered states of consciousness in the five-dimensional space: An empirical study]. Master's thesis, University of Zürich.
10. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005a ; 17: 1497-1508 (Pubitemid 41510955)
11. Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl). 2007 ; 195: 415-424 (Pubitemid 350161767)
12. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. Neuroreport. 2004 ; 15: 1947-1951 (Pubitemid 39180619)
13. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, et al. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology. 2005b ; 30: 1154-1162 (Pubitemid 40720974)
14. Cerletti A Neuro-Pharmacology. Bradley PB Deniker P Radouco-Thomas C, ed. Amsterdam: Elsevier Publishing Company ; 1959 :
15. Chandler AL, Hartman MA. Lysergic acid diethylamide (LSD-25) as a Facilitating Agent in Psychotherapy. Arch Gen Psychiatry. 1960 ; 2: 286-299
16. Clark B. Some early observations on the use of psilocybin in psychiatric patients. Brit J Soc Psychiat. 1968 ; 2: 21-25
17. Cohen S. Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis. 1960 ; 130: 30-40
18. David AE, David JM. La psilocibina, un nuevo alucinógeno, y sus posibilidades terapéuticas en psicoterapia [Psilocybin, a new hallucinogen, and its therapeutic possibilities in psychotherapy]. Acta Neuropsiquiatr Argent. 1961 ; 7: 143-144
19. Deneau G, Yanagita T, Seevers MH. Self-administration of psychoactive substances by the monkey. Psychopharmacologia. 1969 ; 16: 30-48
20. Derogatis LR SCL-90-R: Symptom Checklist-90-R. Administration, scoring and procedures manual. Minneapolis: National Computer Systems, Inc ; 1994 :
21. Dittrich A 50 Years of LSD. Current Status and Perspectives of Hallucinogens. Pletscher A Ladewig D, ed. New York: Parthenon Publishing ; 1994 :
22. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998 ; 31: 80-84 (Pubitemid 28396276)
23. Dittrich A, Lamparter D, Maurer M 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung. [5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction]. Zürich: PSIN Plus Publications ; 2006 :
24. Dittrich A, von Arx S, Staub S. International study on altered states of consciousness (ISASC). Summary of the results. Germ J Psych. 1985 ; 9: 319-339
25. Doblin R. Pahnke's Good Friday experiment: a long-term follow-up and methodological critique. J Transpersonal Psychol. 1991 ; 23: 1-28
26. El-Mallakh RS, Halpern JH, Abraham HD Psychiatry. Tasman A Maj M First MB Kay J Lieberman JA, ed. New York: Wiley ; 2008 :
27. Espiard ML, Lecardeur L, Abadie P, Halbecq I, Dollfus S. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Eur Psychiatry. 2005 ; 20: 458-460 (Pubitemid 41318015)
28. Fahrenberg J, Hampel R, Selg H Das Freiburger Persö nlichkeitsinventar FPI [The Freiburg Personality Inventory FPI]. Göttingen: Hogrefe ; 1984 :
29. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008 ; 75: 17-33 (Pubitemid 350235393)
30. Fischer R. A cartography of the ecstatic and meditative states. Science. 1971 ; 174: 897-904
31. Fischer R, Hill R, Thatcher K, Scheib J. Psilocybin-induced contraction of nearby visual space. Agents Actions. 1970 ; 1: 190-197
32. Fischer R, Hill RM, Warshay D. Effects of psychodysleptic drug psilocybin on visual perception. Changes in brightness preference. Experientia. 1969 ; 25: 166-169
33. Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008 ; 29: 445-453
34. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008 ; 452: 93-97 (Pubitemid 351355090)
35. Gonzalez-Maeso J, Sealfon SC. Agonist-trafficking and hallucinogens. Curr Med Chem. 2009 ; 16: 1017-1027
36. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007 ; 53: 439-452 (Pubitemid 46161267)
37. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, et al. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol. 1998a ; 9: 561-566 (Pubitemid 28552549)
38. Gouzoulis-Mayfrank E, Schneider F, Friedrich J, Spitzer M, Thelen B, Sass H. Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry. 1998b ; 31: 114-118 (Pubitemid 28396281)
39. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, et al. Neurometabolic effects of psilocybin, 3,4- methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999a ; 20: 565-581 (Pubitemid 29189261)
40. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers-Results of an experimental double-blind placebo controlled study. Psychopharmacology. 1999b ; 142: 41-50 (Pubitemid 29196062)
41. Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008 ; 22: 621-632
42. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006 ; 187: 268-283 (Pubitemid 44088380)
43. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. (2009) A pilot study of psilocybin treatment in advanced-stage cancer patients with anxiety. Trial Registration: clinicaltrials.gov Identifier: NCT00302744.
44. Guzmán G, Allen JW, Gartz J. A worldwide geographical distribution of the neurotropic fungi, an analysis and a discusstion. Ann Mus Civico Rovereto. 2000 ; 14: 189-280
45. Halpern JH, Pope Jr. Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug Alcohol Depend. 2003 ; 69: 109-119 (Pubitemid 36259773)
46. Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997 ; 72: 175-184 (Pubitemid 27246716)
47. Hasler F, Bourquin D, Brenneisen R, Vollenweider FX. Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal. 2002 ; 30: 331-339 (Pubitemid 35013499)
48. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004 ; 172: 145-156 (Pubitemid 38388763)
49. Hasler F, Quednow BB, Treyer V, Schubiger PA, Buck A, Vollenweider FX. Role of prefrontal serotonin-2A receptors in self-experience during psilocybin-induced altered states. Neuropsychobiology. 2009 ; 59: 2-2
50. Heekeren K, Daumann J, Neukirch A, Stock C, Kawohl W, Norra C, et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl). 2008 ; 199: 77-88
51. Heimann H. Ausdrucksphänomenologie der Modellpsychosen (Psilocybin). Vergleich mit Selbstschilderung und psychischem Leistungsausfall. [Expressive phenomenology of model psychoses (psilocybin). Comparison with self-description and psychic deficiency of performance.]. Psychiat Neurol. 1961 ; 141: 69-100
52. Heimann H. Zur Behandlung therapieresistenter Neurosen mit Modellpsychosen (Psilocybin) [On the treatment of therapy-resistant neuroses with model psychoses (psilocybin)]. Schweiz Arch Neurol Neurochir Psychiatr. 1962 ; 89: 214-220
53. Hermle L, Kovar KA, Hewer W, Ruchsow M. Hallucinogen-induced psychological disorders. Fortschr Neurol Psychiatr. 2008 ; 76: 334-342 (Pubitemid 351986623)
54. Hill RM, Fischer R, Warshay D. Effects of excitatory and tranquilizing drugs on visual perception. Spatial distortion thresholds. Experientia. 1969 ; 25: 171-172
55. Hillebrand J, Olszewski D and Sedefov R (2006) EMCDDA Thematic Papers-Hallucinogenic Mushrooms: An Emerging Trend Case Study. European Monitoring Centre for Drugs and Drugs Addiction. Retrieved from: http://www.emcdda.europa.eu/html.cfm/index31208EN.html (24 June 2010).
56. Hofmann A Chemical constitution and pharmacodynamic actions. Burger A, ed. New York: M. Dekker ; 1968 :
57. Hofmann A, Heim R, Brack A, Kobel H. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim [Psilocybin, a psychotropic substance from the Mexican mushroom Psilocybe mexicana Heim.]. Experientia. 1958 ; 14: 107-109
58. Hofmann A, Heim R, Brack A, Kobel H, Frey A, Ott H, et al. Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen [Psilocybin and Psilocin, two psychotropic substances from Mexican mushrooms]. Helv Chim Acta. 1959 ; 42: 1557-1572
59. Hollister LE. Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther. 1961 ; 130: 42-52
60. Hollister LE, Hartman AM. Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures. Compr Psychiatry. 1962 ; 3: 235-242
61. Holsten F. Flashbacks: a personal follow-up. Arch Psychiatr Nervenkr. 1976 ; 222: 293-304
62. Horowitz MJ. Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry. 1969 ; 126: 565-569
63. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008 ; 50: 346-363
64. Isbell H. Comparison of reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia. 1959 ; 1: 29-38
65. Janke W, Debus G Die Eigenschaftswörterliste (EWL-K) [The Adjective Word List EWL-K]. Göttingen: Hogrefe ; 1978 :
66. Janke W, Debus G Die Eigenschaftswörterliste EWL 60 S [The Adjective Word List EWL-60 S]. Internationale Skalen für Psychiatrie. Weinheim: Beltz ; 1986 :
67. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008 ; 22: 603-620
68. Leuner H Die experimentelle Psychose [The Experimental Psychosis]. Berlin Göttingen Heidelberg: Springer ; 1962 :
69. Leuner H. Halluzinogene in der Psychotherapie [Hallucinogens in psychotherapy]. Pharmakopsychiatr Neuropsychopharmakol. 1971 ; 4: 333-351
70. Leuner H. Ist die Verwendung von LSD-25 für die experimentelle Psychiatrie und in der Psychotherapie heute noch vertretbar? [Is the use of LSD-25 in experimental psychiatry and psychotherapy today still justifiable?]. Nervenarzt. 1968 ; 39: 356-360
71. Leuner H Halluzinogene: Psychische Grenzzustände in Forschung und Therapie [Hallucinogens: Psychological Borderline States in Research and Therapy]. Bern: Hans Huber ; 1981 :
72. McGlothlin WH, Arnold DO. LSD revisited. A ten-year follow-up of medical LSD use. Arch Gen Psychiatry. 1971 ; 24: 35-49
73. McGlothlin WH, Cohen S, McGlothlin MS. Long lasting effects of LSD on normals. Arch Gen Psychiatry. 1967 ; 17: 521-532
74. Metzner R, Litwin G, Weil GM. The relation of expectation and mood to psilocybin reactions: A questionnaire study. Psychedelic Rev. 1965 ; 5: 3-39
75. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 ; 67: 1735-1740 (Pubitemid 44955154)
76. Moskowitz D. Use of haloperidol to reduce LSD flashbacks. Mil Med. 1971 ; 136: 754-756
77. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181 (Pubitemid 38167565)
78. Nichols DE, Chemel BR The neuropharmacology of religious experience: Hallucinogens and the experience of the divine. Where God and Science meet. How brain and evolutionary studies alter our understanding of religion. Westport: Prager ; 2006 :
79. Nieto D. Psicosis experimentales con Psilocybina [Experimental Psychosis with Psilocybin]. Neurol Neuocir Psiquiat. 1962 ; 3: 140-146
80. O'Brian CP Goodman And Gilman's The Pharmacological Basis of Therapeutics. Brunton LL Lazo JS Parker KL, ed. New York: McGraw-Hill Professional ; 2005 :
81. Pahnke W. Psychedelic drugs and mystical experience. Int Psychiatry Clin. 1969 ; 5: 149-162
82. Passie T. Psilocybin in der modernen Psychotherapie [Psilocybin in modern psychotherapy]. Curare. 1995 ; 18: 131-152
83. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002 ; 7: 357-364 (Pubitemid 35402507)
84. Pinheiro JC, Bates DM Mixed-Effects Models in S and S-Plus. New York: Springer Verlag ; 2000 :
85. Pinheiro JC, Bates DM, DebRoy S, Sarkar S, Core Team R. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-90 ed. 2008 ;:
86. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org. 2008 ;:
87. Rinkel MA, DiMascio A, Robey A, Atwell C Neuro-Psychopharmacology. Bradley PB, ed. Amsterdam: Elsevier ; 1961 :
88. Rümmele W, Gnirss F. Untersuchungen mit Psilocybin, einer psychotropen Substanz aus Psilocybe Mexicana [Investigations with psilocybin, a psychotropic substance from Psilocybe Mexicana]. Schweiz Arch Neurol Psychiatr. 1961 ; 87: 365-385
89. Sanders-Bush E, Burries KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther. 1988 ; 246: 924-928
90. Sandison RA. Psychological aspects of the LSD treatment of neuroses. J Ment Sci. 1954 ; 100: 508-515
91. Sandison RA, Whitelaw JD. Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci. 1957 ; 103: 332-343
92. Spitzer M, Thimm M, Hermle L, Holzmann P, Kovar KA, Heimann H, et al. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry. 1996 ; 39: 1055-1057 (Pubitemid 26192905)
93. Stamets P Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, CA: Ten Speed Press ; 1996 :
94. Strassman RJ. Adverse reaction to psychedelic drugs. A review of the literature. J Nerv Ment Dis. 1984 ; 172: 577-595 (Pubitemid 15200405)
95. Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry. 2002 ; 51: 400-406 (Pubitemid 34251177)
96. Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T, et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2003 ; 28: 170-181
97. Vollenweider FX. Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichtigung der Ketamin/PCP-Modell-Psychose [The use of psychotomimetics in schizophrenia research with special emphasis on the PCP/ketamine model psychosis]. SUCHT Wissenschaft Praxis. 1992 ; 38: 398-409 (Pubitemid 23046327)
98. Vollenweider FX. Advances and pathophysiological models of hallucinogen drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry. 1998 ; 31: 92-103 (Pubitemid 28396278)
99. Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 2001 ; 3: 265-279
100. Vollenweider FX, Geyer MA. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull. 2001 ; 56: 495-507 (Pubitemid 34031785)
101. Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 2007 ; 32: 1876-1887 (Pubitemid 47258517)
102. Vollenweider FX, Hasler F, Kometer M. Effects of serotonergic hallucinogens on perception and patterns of altanserin displacement in humans. Fundam Clin Pharmacol. 2008 ; 22: 113-113
103. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997 ; 16: 357-372 (Pubitemid 27211734)
104. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998 ; 9: 3897-3902 (Pubitemid 29189323)
105. Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: A PET study with [11C]raclopride. Neuropsychopharmacology. 1999 ; 20: 424-433 (Pubitemid 29123870)
106. von Zerssen D. Die Beschwerden-Liste als Test [The list of complaints as test]. Therapiewoche. 1971 ; 25: 1908-1920
107. Wackermann J, Wittmann M, Hasler F, Vollenweider FX. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci Lett. 2008 ; 435: 51-55
108. Wasson RG Les champignons hallucinogenes du Mexique [The hallucinogenic mushrooms of Mexico]. Heim R Wasson RG Hofmann A, ed. Paris: Editions du Museum National d'Histoire Naturelle ; 1958 :
109. Wittchen HU, Pfister H DIA-X-Interview. Frankfurt: Swets Test Services ; 1997 :
110. Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007 ; 21: 50-64 (Pubitemid 46012083)
111. Wolbach AB, Miner EJ, Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 1962 ; 3: 219-223